# A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer

> **NCT04993430** · PHASE1 · UNKNOWN · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- ER-Positive, HER2-Negative Breast Cancer

## Interventions

- **DRUG:** HRS8807
- **DRUG:** HRS8807
- **DEVICE:** HRS8807、SHR6390
- **DRUG:** HRS8807、SHR6390

## Key facts

- **NCT ID:** NCT04993430
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-26
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2021-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04993430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04993430, "A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04993430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*